LivaNova PLC Announces 2024 Annual General Meeting on June 11

Ticker: LIVN · Form: DEF 14A · Filed: 2024-04-26T00:00:00.000Z

Sentiment: neutral

Topics: LivaNova, AGM, Proxy Statement, Shareholders, Virtual Meeting

TL;DR

<b>LivaNova PLC will host its 2024 virtual Annual General Meeting on June 11, 2024, for shareholders of record as of April 15, 2024.</b>

AI Summary

LivaNova PLC (LIVN) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. LivaNova PLC will hold its 2024 Annual General Meeting (AGM) on Tuesday, June 11, 2024. The meeting will be conducted virtually at www.meetnow.global/MS6WDW6. Shareholders of record as of April 15, 2024, are eligible to attend. The company has one class of voting share: Ordinary Shares. As of April 15, 2024, there were [data unavailable] Ordinary Shares outstanding.

Why It Matters

For investors and stakeholders tracking LivaNova PLC, this filing contains several important signals. This filing is a Definitive Proxy Statement (DEF 14A), indicating it contains important information for shareholders regarding the upcoming AGM and voting procedures. The virtual format of the meeting allows for broader shareholder participation regardless of geographical location, facilitating engagement with company management and voting on resolutions.

Risk Assessment

Risk Level: low — LivaNova PLC shows low risk based on this filing. The filing is a routine proxy statement for an annual general meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Shareholders should review the proxy statement to understand the proposals being voted on and how to participate in the virtual AGM.

Key Numbers

Key Players & Entities

FAQ

When did LivaNova PLC file this DEF 14A?

LivaNova PLC filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by LivaNova PLC (LIVN).

Where can I read the original DEF 14A filing from LivaNova PLC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LivaNova PLC.

What are the key takeaways from LivaNova PLC's DEF 14A?

LivaNova PLC filed this DEF 14A on April 26, 2024. Key takeaways: LivaNova PLC will hold its 2024 Annual General Meeting (AGM) on Tuesday, June 11, 2024.. The meeting will be conducted virtually at www.meetnow.global/MS6WDW6.. Shareholders of record as of April 15, 2024, are eligible to attend..

Is LivaNova PLC a risky investment based on this filing?

Based on this DEF 14A, LivaNova PLC presents a relatively low-risk profile. The filing is a routine proxy statement for an annual general meeting, with no immediate financial or operational disclosures that would indicate high risk.

What should investors do after reading LivaNova PLC's DEF 14A?

Shareholders should review the proxy statement to understand the proposals being voted on and how to participate in the virtual AGM. The overall sentiment from this filing is neutral.

How does LivaNova PLC compare to its industry peers?

LivaNova PLC operates in the electromedical and electrotherapeutic apparatus industry, focusing on medical devices.

Are there regulatory concerns for LivaNova PLC?

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

Industry Context

LivaNova PLC operates in the electromedical and electrotherapeutic apparatus industry, focusing on medical devices.

Regulatory Implications

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

What Investors Should Do

  1. Shareholders should register for the virtual AGM at www.meetnow.global/MS6WDW6.
  2. Review the proxy statement for details on proposals and voting procedures.
  3. Ensure your Ordinary Shares are registered by the April 15, 2024 record date to be eligible to vote.

Key Dates

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual General Meeting proxy statement.

Filing Stats: 4,577 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2024-04-26 16:02:06

Filing Documents

Executive Compensation

Executive Compensation 26 Compensation Discussion & Analysis 26 Compensation and Human Capital Management Committee Report 43 Compensation Tables 44 Pay Versus Performance Disclosure 57 Proposals to be Acted Upon at the AGM 61 Proposal No. 1—Election of Directors 61 Proposal No. 2—Advisory (Non-Binding) Vote to Approve Executive Compensation (Say on Pay) 62 Proposal No. 3—Ratification of the Appointment of PwC-US as the Company's Independent Registered Public Accounting Firm 62 Proposal No. 4—Approval of Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan 65 Proposal No. 5—Approval of Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan 72 Proposal No. 6—Ordinary Resolution to Grant Authority to Allot Shares 80 Proposal No. 7—Special Resolution to Grant Power to Disapply Pre-Emption Rights 80 Proposal No. 8—Advisory Vote to Approve the UK Directors' Remuneration Report 82 Proposal No. 9—To Receive and Adopt the UK Annual Report and Accounts 82 Proposal No. 10—Re-appointment of PwC-UK as the Company's UK Statutory Auditor 83 Proposal No. 11—Authorization of the Directors and/or the Audit and Compliance Committee to Determine the Remuneration of PwC-UK in its Capacity as UK Statutory Auditor 83 Other Information 84 Frequently Asked Questions About the Annual General Meeting 87 Appendix A A-1 Appendix B B-1 vii TABLE OF CONTENTS Proxy Summary This summary highlights information described in greater detail later in this proxy statement. Please read the proxy statement in its entirety and do not rely on this summary to give you the information you need to make an informed decision on the proposals presented for your consideration. Governance Highlights LivaNova is committed to good corporate governance, which promotes the long-term interests of the Company's shareholders and strengthens the Board and management accountability. Many of Li

: Gender Identity

Part I: Gender Identity Directors 3 7 0 0

: Demographic Background

Part II: Demographic Background African American or Black 1 * 0 0 White 2 6 0 Hispanic or Latinx 0 1 ** 0 * Brooke Story ** Francesco Bianchi The following individuals are nominated for election at the AGM. Name Occupation Independent Age Director Since Audit and Compliance Committee Compensation and Human Capital Management Committee Nominating and Corporate Governance Committee William Kozy (Chair of the Board) Former EVP and COO, Becton, Dickinson and Company Yes 72 2018 J. Christopher Barry Executive Vice President and Group President of the Medical Solutions Division, 3M Company Yes 52 2023 X Francesco Bianchi Chair, Seven Capital Partners S.r.l. Yes 67 2015 X X Stacy Enxing Seng Operating Partner, Lightstone Ventures Yes 59 2019 Chair Vladimir Makatsaria CEO, LivaNova No 51 2024 2 TABLE OF CONTENTS Name Occupation Independent Age Director Since Audit and Compliance Committee Compensation and Human Capital Management Committee Nominating and Corporate Governance Committee Dr. Sharon O'Kane Non-Executive Director of the Health Products Regulatory Authority Board in Ireland; Entrepreneur in Residence, University College Dublin Yes 56 2015 Chair Todd Schermerhorn Former SVP and Chief Financial Officer, C.R. Bard, Inc. Yes 63 2020 Chair Brooke Story Former Worldwide President, Surgery, Becton, Dickinson and Company Yes 52 2022 X Peter Wilver Former EVP and Chief Administrative Officer, Thermo Fisher Scientific Inc. Yes 64 2022 X X Approach to Executive Compensation LivaNova's market-competitive executive compensation program acts as an incentive for the Company's named executive officers ("NEOs") to perform at their highest level, take appropriate risks and drive shareholder return in the short and long term. LivaNova's executive compensatio

View on Read The Filing